AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Imfinzi (durvalumab) — Europe product sales by Year
Imfinzi (durvalumab) — Europe product sales ($M) ($M)
AstraZeneca Imfinzi (durvalumab) — Europe product sales: $1,239M in FY2025, up 30.7% from a year earlier.
Where the FY2025 figure comes from
“|| Imfinzi | 6,063 | 29 | 28 | 3,509 | 35 | 640 | 34 | 38 | 1,239 | 31 | 26 | 675 | (2) | (2)”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Imfinzi (durvalumab) — Europe product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,239 | +30.7% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 948 | +25.1% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 758 | +39.3% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 544 | +12.2% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 485 | +31.1% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 370 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up imfinzi (durvalumab) — Europe product sales
Cite this data
StockData. (2026). AstraZeneca Imfinzi (durvalumab) — Europe product sales ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-imfinzi-eu
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.